Highest-materiality recent filing
Jupiter Neurosciences signs exclusive US license for PharmAla's ALA-002 MDMA program
Upfront payment of $3.33M: $1.5M cash (net of $600K escrow) plus $1.83M in Jupiter common stock.
Jupiter Neurosciences appoints Tomas J. Philipson, Ph.D. to Board
Appointed effective June 26, 2026; will serve on Audit and Compensation Committees.
Director Allison W. Brady resigns from Jupiter Neurosciences Board effective June 17, 2026
Allison W. Brady resigned from the Board, Audit Committee and Compensation Committee effective June 17, 2026.
Jupiter Neurosciences names Silva COO/President; awards options to execs and directors
Alison Silva appointed COO and President; base salary raised to $340,200 from $315,000.
Jupiter Neurosciences announces $2M registered direct offering of 7.1M shares at $0.28/share
7,142,858 shares sold at $0.28 per share for gross proceeds of ~$2.0M.
Jupiter Neurosciences signs $3.33M non-binding term sheet for exclusive U.S. rights to ALA-002 MDMA
Upfront consideration $3.33M ($1.5M cash + $1.83M JUNS stock with 120-day lock-up); $600K escrow deposited.
Jupiter Neurosciences receives Nasdaq deficiency notices for bid price and market value
Two Nasdaq deficiency notices received Feb 26, 2026: bid price <$1.00 for 30 consecutive days.
Jupiter Neurosciences extends payment start on $6M Yorkville convertible notes to April 2026
Omnibus Amendment signed Feb 20, 2026 with Yorkville to revise monthly payment terms.
Jupiter Neurosciences draws $1.86M second tranche from Yorkville SEPA; stockholder approval obtained
Second Pre-Paid Advance closing on Dec 23, 2025: $1,860,000 disbursed to Jupiter Neurosciences.
Authorized common stock increased from 125M to 500M shares via amendment approved by 20.2M votes for, 4.5M against.
Corrects outstanding shares as of October 24, 2025 from 34,833,083 to 34,294,446.
Jupiter Neurosciences secures up to $20M flexible financing from Yorkville; $4M funded at signing
Initial $4M pre-paid advance funded via convertible note with $1.50 fixed conversion price and 7% OID.
Jupiter Neurosciences regains Nasdaq minimum bid price compliance
Nasdaq confirmed compliance on July 9, 2025 after closing bid price ≥ $1.00 for 13 consecutive days (June 18 – July 8, 2025).
Jupiter Neurosciences grants stock options and conditional cash bonuses to executives
Alison Silva granted 255,320 options; Saleem Elmassri granted 102,128 options; exercise price $1.19, 3-yr vest, 10-yr term.
Jupiter Neurosciences replaces auditor; prior reports flagged going concern
Assurance Dimensions resigned as auditor effective April 16, 2025 due to discontinuation of PCAOB practice.
Jupiter Neurosciences receives Nasdaq delisting notice for bid price non-compliance
Nasdaq notified JUNS on Mar 21, 2025 that bid price closed below $1.00 for 30 consecutive business days through Mar 20, 2025.
Jupiter Neurosciences revises CFO compensation: monthly fee to Titan increases to $20k for 2025
Monthly fee for CFO services via Titan Advisory Services LLC set at $20,000 for 2025, up from $5,000 during reduction period.
One-time payment of $2,300,000 to Dominant Treasure for services to accelerate product development and distribution in Southeast Asia.
Jupiter Neurosciences closes IPO on Nasdaq, raises $11M gross from 2.75M shares at $4.00
IPO of 2,750,000 common shares priced at $4.00/sh for gross proceeds of $11M.
Jupiter Neurosciences extends maturity of $1.38M in secured notes by 26 days to Dec 11, 2024
Extended Puritan Note ($1,111,111) and Assigned Note ($266,667) maturity from Nov 15 to Dec 11, 2024.
On June 17, 2026, Allison W. Brady, a member of the Board of Directors (the “Board”) of Jupiter Neurosciences, Inc. (the “Company”), informed the Company of her decision to resign from the Board, effective immediately.
The Amendment appoints Ms. Silva as the Company’s Chief Operating Officer and President
Max materiality 0.80 · Median 0.53 · Most common event other_material